BIO-TECHNE Corp Revenue
BIO-TECHNE Corp (TECH) reported Revenue of $1.22 billion for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-24
- BIO-TECHNE Corp revenues for the quarter ending 2026-06-30 was $321.19M, a 1.33% increase year-over-year.
- BIO-TECHNE Corp revenues for the quarter ending 2026-03-31 was $311.42M, a 1.51% decline year-over-year.
- BIO-TECHNE Corp revenues for the quarter ending 2025-12-31 was $295.88M, a 0.39% decline year-over-year.
- BIO-TECHNE Corp revenues for the quarter ending 2025-09-30 was $286.56M, a 1.00% decline year-over-year.
- BIO-TECHNE Corp revenues for fiscal 2026 was $1.22B, a 0.38% decline from fiscal 2025.
- BIO-TECHNE Corp revenues for fiscal 2025 was $1.22B, a 5.23% increase from fiscal 2024.
- BIO-TECHNE Corp revenues for fiscal 2024 was $1.16B, a 1.97% increase from fiscal 2023.
- BIO-TECHNE Corp revenues for fiscal 2023 was $1.14B.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $321.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $632.61M derived: sum of 2 quarters · filed 2026-08-24 | $928.48M derived: sum of 3 quarters · filed 2026-08-24 | $1.22B 10-K · filed 2026-08-24 |
| 2026-03-31 | $311.42M 10-Q · filed 2026-05-06 | $607.29M derived: sum of 2 quarters · filed 2026-05-06 | $893.85M 10-Q · filed 2026-05-06 | $1.21B derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-12-31 | $295.88M 10-Q · filed 2026-02-04 | $582.43M 10-Q · filed 2026-02-04 | $899.40M derived: sum of 3 quarters · filed 2026-08-24 | $1.22B derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-09-30 | $286.56M 10-Q · filed 2025-11-05 | $603.52M derived: sum of 2 quarters · filed 2026-08-24 | $919.70M derived: sum of 3 quarters · filed 2026-08-24 | $1.22B derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-06-30 | $316.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $633.14M derived: sum of 2 quarters · filed 2026-08-24 | $930.18M derived: sum of 3 quarters · filed 2026-08-24 | $1.22B 10-K · filed 2026-08-24 |
| 2025-03-31 | $316.18M 10-Q · filed 2026-05-06 | $613.21M derived: sum of 2 quarters · filed 2026-05-06 | $902.67M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $297.03M 10-Q · filed 2026-02-04 | $586.49M 10-Q · filed 2026-02-04 | ||
| 2024-09-30 | $289.46M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $1.16B 10-K · filed 2026-08-24 | |||
| 2023-06-30 | $1.14B 10-K · filed 2025-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |